2026 Interim report
Filed with HKEX · Stock code 9966 · · 83 pages · English
Page Definitions and Glossary of Technical Terms Company Profile Corporate Information Financial Highlights Business Highlights Management Discussion and Analysis Corporate Governance and Other Information Report on Review of Condensed Consolidated Financial Statements 51 Condensed Consolidated Statement of Profit or Loss and Other Comprehensive Income 52 Condensed Consolidated Statement of Financ
Earlier from Alphamab Oncology
- 2026 ASCO Preview | Alphamab Oncology to Present Clinical Data of TROP2/HER3 Bispecific ADC JSKN016 for HER2-Negative Breast Cancer
- 2026 ASCO Preview | Results from Phase III Study of Anbenitamab (KN026) Combined with HB1801 in Neoadjuvant Treatment for Breast Cancer Selected for LBA Oral Presentation
- Alphamab Oncology Announces the Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 as Neoadjuvant Treatment for Breast Cancer Has Met the Primary Endpoint
- Alphamab Oncology Reports Full Year 2025 Financial Results and Business Highlights
- Alphamab Oncology Announces the First Patient Dosed in a Phase III Clinical Study of Anbenitamab (KN026) Combined with HB1801 and Chemotherapy as Adjuvant Treatment of Breast Cancer
Later from Alphamab Oncology
- Next Day Disclosure Return
- Monthly Return of Equity Issuer on Movements in Securities for the month ended 30 September 2026
Follow Alphamab Oncology into a list and get an email when it puts out news.
Follow Alphamab Oncology